Jiangsu Kanion Pharmaceutical Co.,Ltd. Stock: price and insider trades · China
康缘药业
No insider purchase over the last 90 days. The latest, by 刘权, was filed 01 Dec 2025.
Jiangsu Kanion Pharmaceutical Co.,Ltd.: what insiders have been doing
Jiangsu Kanion Pharmaceutical Co.,Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). From 5 November 2025 to 5 November 2026, the disclosure feed for Jiangsu Kanion Pharmaceutical Co.,Ltd. logged 4 filings by 4 insiders.
No insider sold shares on the market over the period. Instead, the filings list 4 purchases totalling €29k, made by 4 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 3 senior executives and 1 board member among the declarants. Biggest ticket of the year: €18k, bought by 杨永春 and made public on 1 December 2025.
In all, 3 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 1 December 2025, 342 days ago. Most trades are made public on the day they happen. This delay matters because a trade only becomes useful information once it is public.
Compared with its exchange (514 companies, median 2 filings), a count of 4 filings is above the norm. Our records for Jiangsu Kanion Pharmaceutical Co.,Ltd. go back to 2023, with 4 purchases and 2 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -15.9%Entry CN¥15.10 · Close 03 Nov 2026 CN¥12.70
- -15.9%Entry CN¥15.10 · Close 03 Nov 2026 CN¥12.70
- -17.2%Entry CN¥15.33 · Close 03 Nov 2026 CN¥12.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,900 shares100.0% of flowA股XSHGSSE:173000009856792700Canonical exit: 1 Mar 2026 (T+90)
- 10,000 shares100.0% of flowA股XSHGSSE:173000009856792740Canonical exit: 1 Mar 2026 (T+90)
- 2,000 shares100.0% of flowA股XSHGSSE:173000009822885630Canonical exit: 19 Feb 2026 (T+90)
- 2,000 shares100.0% of flowA股XSHGSSE:173000009822885440Canonical exit: 18 Feb 2026 (T+90)
- 5,000 shares100.0% of flowA股XSHGSSE:173000007772799970
- 8,600 shares100.0% of flowA股XSHGSSE:173000007485408400
6 of 6 declarations
About Jiangsu Kanion Pharmaceutical Co.,Ltd.
康缘药业 is a company focused on the research, development, and manufacturing of pharmaceutical products. It is listed on the Shanghai Stock Exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
